Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Laboratory Determinations
2.2. Statistical Analysis
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Perico, L.; Benigni, A.; Casiraghi, F.; Ng, L.F.P.; Renia, L.; Remuzzi, G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 2020, 17, 46–64. [Google Scholar] [CrossRef] [PubMed]
- Connors, J.M.; Levy, J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 2033–2040. [Google Scholar] [CrossRef] [PubMed]
- Jiménez, D.; García-Sanchez, A.; Rali, P.; Muriel, A.; Bikdeli, B.; Ruiz-Artacho, P.; Le Mao, R.; Rodríguez, C.; Hunt, B.J.; Monreal, M. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. Chest 2021, 159, 1182–1196. [Google Scholar] [CrossRef] [PubMed]
- REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021, 385, 777–789. [Google Scholar] [CrossRef] [PubMed]
- Mazloomzadeh, S.; Khaleghparast, S.; Ghadrdoost, B.; Mousavizadeh, M.; Baay, M.R.; Noohi, F.; Sezavar, S.H.; Payandemehr, P.; Dabbagh, A.; Moghadam, K.G.; et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021, 325, 1620–1630. [Google Scholar]
- Nannoni, S.; de Groot, R.; Bell, S.; Markus, H.S. Stroke in COVID-19: A systematic review and meta-analysis. Int. J. Stroke 2021, 16, 137–149. [Google Scholar] [CrossRef] [PubMed]
- Solomon, M.D.; McNulty, E.J.; Rana, J.S.; Leong, T.K.; Lee, C.; Sung, S.-H.; Ambrosy, A.P.; Sidney, S.; Go, A.S. The COVID-19 Pandemic and the Incidence of Acute Myocardial Infarction. N. Engl. J. Med. 2020, 383, 691–693. [Google Scholar] [CrossRef] [PubMed]
- De Filippo, O.; D’Ascenzo, F.; Angelini, F.; Bocchino, P.P.; Conrotto, F.; Saglietto, A.; Ospedaliera, A.; Secco, G.G.; Campo, G.; Gallone, G.; et al. Reduced Rate of Hospital Admissions for ACS during COVID-19 Outbreak in Northern Italy. N. Engl. J. Med. 2020, 383, 88–89. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.K.; Fuster, V.; Hofstra, L.; Kini, A.S.; Gianelli, A.; Narula, J. Lessons learned from reduced acute cardiovascular events and STEMI during COVID-19. Catheter. Cardiovasc. Interv. 2021, 97, 850–852. [Google Scholar] [CrossRef] [PubMed]
- Gómez-Mesa, J.E.; Galindo-Coral, S.; Montes, M.C.; Martin, A.J.M. Thrombosis and Coagulopathy in COVID-19. Curr. Probl. Cardiol. 2021, 46, 100742. [Google Scholar] [CrossRef] [PubMed]
- Zeng, F.; Huang, Y.; Guo, Y.; Yin, M.; Chen, X.; Xiao, L.; Deng, G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int. J. Infect. Dis. 2020, 96, 467–474. [Google Scholar] [CrossRef] [PubMed]
- Velavan, T.P.; Meyer, C.G. Mild versus severe COVID-19: Laboratory markers. Int. J. Infect. Dis. 2020, 95, 304–307. [Google Scholar] [CrossRef] [PubMed]
- Instituto Nacional de Estatística. COVID-19: Uma Leitura do Contexto Demográfico e da Expressão Territorial da Pandemia, 4 de Dezembro de 2020; INE, Instituto Nacional de Estatística: Lisboa, Portugal, 2020. Available online: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=467657626&DESTAQUESmodo=2 (accessed on 4 December 2021).
- Hill, J.B.; Garcia, D.; Crowther, M.; Savage, B.; Peress, S.; Chang, K.; Deitelzweig, S. Frequency of venous thromboembolism in 6513 patients with COVID-19: A retrospective study. Blood Adv. 2020, 4, 5373–5377. [Google Scholar] [CrossRef] [PubMed]
- Nopp, S.; Moik, F.; Jilma, B.; Pabinger, I.; Ay, C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res. Pract. Thromb. Haemost. 2020, 4, 1178–1191. [Google Scholar] [CrossRef] [PubMed]
- Tremblay, D.; Van Gerwen, M.; Alsen, M.; Thibaud, S.; Kessler, A.J.; Venugopal, S.; Makki, I.; Qin, Q.; Dharmapuri, S.; Jun, T.; et al. Impact of anticoagulation prior to COVID-19 infection: A propensity score–matched cohort study. Blood 2020, 136, 144–147. [Google Scholar] [CrossRef] [PubMed]
- Hottz, E.D.; Azevedo-Quintanilha, I.G.; Palhinha, L.; Teixeira, L.; Barreto, E.A.; Pão, C.R.R.; Righy, C.; Franco, S.; Souza, T.M.L.; Kurtz, P.; et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020, 136, 1330–1341. [Google Scholar] [CrossRef] [PubMed]
- Shalhub, S. The mystery of COVID-19-associated arterial thrombosis. J. Vasc. Surg. 2021, 73, 390–391. [Google Scholar] [CrossRef] [PubMed]
TE | Non-TE | |
---|---|---|
Number of patients | 25 | 24 |
Male/:Female ratio | 18/:6 | 18/:7 |
Age (years) | 70.64 ± 13.43 | 72.67 ± 4.66 |
Patients in ICU | 17 | 17 |
Co-morbidities | ||
Obesity | 9 | 9 |
IT Diabetes Mellitus 2 | 1 | 1 |
Non-IT Diabetes Mellitus 2 | 7 | 6 |
Hypertension | 14 | 14 |
Statin Therapy | 9 | 9 |
Obstructive Sleep Apnoea | 2 | 2 |
Asthma | 1 | 0 |
COPD | 1 | 1 |
Cardiac Pacemaker | 1 | 1 |
Atrial Fibrillation | 3 | 2 |
Atherosclerosis | 4 | 4 |
Active Neoplasia | 1 | 0 |
Renal Transplant | 1 | 0 |
Systemic Lupus erythematosus | 1 | 0 |
HIV/HCV co-infection | 1 | 1 |
COVID-19 Patients | N = 290 |
Thrombotic Events | N (%) |
TE | 25 (8.62%) |
Isolated VTE | 7 (2.41%) |
Isolated ATE | 16 (5.52%) |
Multiple Mixed Events | 2 (0.69%) |
VTE | 7 (28%) |
Pulmonary Embolism | 4 |
Venous Sinus Thrombosis | 1 |
Superior Vena Cava Thrombosis | 1 |
Deep Leg Vein Thrombosis | 1 |
ATE | 16 (64%) |
Ischemic Stroke | 11 |
ST—elevation Myocardial Infarction | 5 |
Multiple Mixed Events | 2 (8%) |
TE upon hospital admission | 17 (68%) |
ATE | 13 (52%) |
VTE | 4 (16%) |
Admission Levels | Non-TE | TE | ATE | VTE | TE/Non-TE | ATE/Non-TE | VTE/Non-TE | ATE/VTE |
---|---|---|---|---|---|---|---|---|
CRP (mg/L) (0–5.0) | 126.44 (100.59–181.04) | 77.00 (13.51–169.46) | 41.61 (7.76–136.73) | 78.36 (41.20–214.96) | p = 0.021 | p = 0.007 | p = 0.219 | p = 0.204 |
D-dimer (ng/mL) (<500) | 753.50 (362.75–1112.25) | 1128.00 (451.00–5250.00) | 666.00 (420.00–1428.00) | 2645.00 (871.00–5250.00) | p = 0.049 | p = 0.526 | p = 0.014 | p = 0.138 |
LDH (U/L) (135–214) | 361.00 (270.00–491.50) | 356.50 (204.25–553.75) | 237.00 (189.00–371.00) | 478.00 (392.00–561.00) | p = 0.690 | p = 0.037 | p = 0.130 | p = 0.018 |
Ferritin (ng/mL) (2.20–178) | 1555.00 (887.00–2158.00) | 1219.50 (324.75–1977.50) | 730.00 (299.75–1483.00) | 1707.00 (808.00–2318.00) | p = 0.235 | p = 0.045 | p = 0.294 | p = 0.205 |
Fibrinogen (g/L) (1.7–2.5) | 6.20 (4.56–7.22) | 4.63 (3.51–5.00) | 4.41 (3.32–4.94) | 4.35 (3.73–7.30) | p = 0.014 | p = 0.010 | p = 0.232 | p = 0.409 |
Monocytes (103/μL) (0.20–0.80) | 0.44 (0.30–0.70) | 0.64 (0.36–0.88) | 0.67 (0.52–0.89) | 0.35 (0.32–0.78) | p = 0.095 | p = 0.033 | p = 0.850 | p = 0.141 |
Hemoglobin (g/dL) (Male:13–17) (Female:12–15) | 13.95 (12.68–14.56) | 13.80 (12.95–14.35) | 13.50 (12.73–14.18) | 14.20 (13.3–14.5) | p = 0.802 | p = 0.214 | p = 0.586 | p = 0.076 |
Leucocytes (103/μL) (4.00–11.00) | 6.47 (5.60–8.88) | 8.18 (5.05–11.25) | 8.21 (6.16–10.20) | 6.59 (4.86–14.08) | p = 0.390 | p = 0.639 | p = 0.850 | p = 0.841 |
Neutrophils (103/μL) (2.0–7.5) | 5.17 (3.93–6.77) | 5.98 (3.99–9.94) | 6.12 (3.85–8.31) | 5.88 (4.11–11.17) | p = 0.624 | p = 0.858 | p = 0.671 | p = 0.462 |
Lymphocytes (103/μL) (1.50–4.00) | 0.93 (0.53–1.13) | 0.84 (0.54–1.42) | 0.87 (0.64–1.42) | 0.55 (0.42–1.44) | p = 0.749 | p = 0.269 | p = 0.539 | p = 0.256 |
Platelets (103/μL) (150–400) | 188 (157–251) | 207 (163–309) | 203 (163.50–301.50) | 221 (133–332) | p = 0.503 | p = 0.772 | p = 0.603 | p = 1.000 |
Myoglobin (μg/L) (28–72) | 62.20 (40.60–218.00) | 65.90 (42.85–132.50) | 75.45 (40.03–200.00) | 63 (45.00–82.20) | p = 0.735 | p = 0.774 | p = 0.623 | p = 0.663 |
Creatine Kinase (IU/L) (24–204) | 90.95 (48.25–214.55) | 163.50 (107.75–294.10) | 166.55 (96.78–271.23) | 120.30 (105.90–190.30) | p = 0.158 | p = 0.327 | p = 0.293 | p = 0.551 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
de Oliveira, M.; Cubal, F.; Coutinho, M.; Pereira, M.; Cruz, E.; Morais, S. Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. Viruses 2022, 14, 2330. https://doi.org/10.3390/v14112330
de Oliveira M, Cubal F, Coutinho M, Pereira M, Cruz E, Morais S. Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. Viruses. 2022; 14(11):2330. https://doi.org/10.3390/v14112330
Chicago/Turabian Stylede Oliveira, Miguel, Francisco Cubal, Maria Coutinho, Mónica Pereira, Eugénia Cruz, and Sara Morais. 2022. "Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis" Viruses 14, no. 11: 2330. https://doi.org/10.3390/v14112330
APA Stylede Oliveira, M., Cubal, F., Coutinho, M., Pereira, M., Cruz, E., & Morais, S. (2022). Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. Viruses, 14(11), 2330. https://doi.org/10.3390/v14112330